Roche Applied Science said this week that it introduced the new xCELLigence RTCA MP instrument two weeks ago. In comparison with the xCELLigence RTCA SP, the new RTCA MP Instrument has a higher throughput capacity and it is more versatile, which enables application on a wider range of experimental set-ups, the company said.
The new system features six E-Plate 96 microtiter plates, as opposed to only one in the RTCA SP. Each E-Plate can be individually addressed in independent experiments, to allow a group of researchers to work simultaneously. According to Roche, the first systems have already been delivered to major pharmaceutical companies.
The xCELLigence technology features a micro-electronic biosensor built into each well of the standard 96-well E-Plate. A cell which has contact with the sensor changes the electrical impedance between the microelectrodes.
Each change in the cell's status — for example, changes in cell adhesion, cytotoxicity, cell proliferation, cell-cell interactions, and morphological changes — leads to changes in the impedance measurements, and can therefore be detected in real time. Labeling of the cells or the use of reporters is not necessary.